Federated Hermes Inc. Has $106.40 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Federated Hermes Inc. raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 294.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,450,704 shares of the biopharmaceutical company’s stock after purchasing an additional 1,082,638 shares during the quarter. Federated Hermes Inc. owned approximately 1.24% of Halozyme Therapeutics worth $106,395,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HALO. Empowered Funds LLC bought a new position in shares of Halozyme Therapeutics in the first quarter valued at $755,000. Acadian Asset Management LLC bought a new position in shares of Halozyme Therapeutics in the 1st quarter valued at about $195,000. Public Employees Retirement System of Ohio increased its stake in shares of Halozyme Therapeutics by 6,594.3% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 38,626 shares of the biopharmaceutical company’s stock worth $2,009,000 after purchasing an additional 38,049 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in shares of Halozyme Therapeutics by 31.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 61,818 shares of the biopharmaceutical company’s stock valued at $3,214,000 after purchasing an additional 14,915 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Halozyme Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,760 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 639 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

HALO opened at $72.83 on Thursday. The business has a fifty day simple moving average of $68.82 and a 200 day simple moving average of $68.23. The company has a market capitalization of $8.56 billion, a PE ratio of 15.33, a price-to-earnings-growth ratio of 0.31 and a beta of 0.94. Halozyme Therapeutics, Inc. has a 1 year low of $47.50 and a 1 year high of $79.50. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. The firm had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The company’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter last year, the business earned $1.27 EPS. Research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity

In other news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the sale, the director directly owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Helen Torley sold 16,569 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $68.92, for a total value of $1,141,935.48. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at approximately $48,844,913.48. This trade represents a 2.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 45,661 shares of company stock worth $3,139,257. Corporate insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of recent analyst reports. Morgan Stanley lowered their price target on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research report on Monday, October 20th. Citizens Jmp boosted their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. Zacks Research cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Finally, The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and an average target price of $78.80.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Raised guidance and multi‑year outlook — Halozyme updated preliminary 2025 results and raised full‑year 2026 and multi‑year guidance, increasing revenue, royalty and adjusted EBITDA ranges and raising non‑GAAP EPS. Management projects royalty revenue above $1B and called out sustained ENHANZE momentum as the driver. Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
• Positive Sentiment: Acquisition expands delivery platform — Halozyme closed its purchase of Surf Bio (hyperconcentration technology) to broaden subcutaneous/biologic delivery capabilities and pipeline optionality; transaction value reported up to ~$400M, signaling inorganic expansion of ENHANZE‑adjacent offerings. Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M
• Positive Sentiment: Long‑term growth narrative strengthened — Analysts/coverage pieces and company commentary point to sustained growth well into the 2030s/2040s driven by expanding ENHANZE royalties, new partnerships and the Surf Bio add‑on, supporting a re‑rating thesis for royalty‑driven cash flow. Halozyme Therapeutics Projects Sustained Growth Well Into 2040
• Neutral Sentiment: Scientific/clinical support for hyaluronidase use — Recent studies and academic reports suggest subcutaneous hyaluronidase can boost delivery/effectiveness in oncology immunotherapy, which reinforces Halozyme’s platform relevance but is not immediate revenue‑driving news. Subcutaneous delivery of hyaluronidase may boost effectiveness of cancer immunotherapy

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.